Research Areas

A Phase 3, Open-Label, Parallel-Group Study to Compare Two Dosing Algorithms for An Investigational Inhaled Insulin in Insulin-Naïve Patients with Type 2 Diabetes Mellitus.

An Open Label, Multicenter, Randomized, Parallel Group Study Comparing the Efficacy and Safety of an Investigational Insulin and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus.

A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose-Range Finding Study of an Investigational Medication in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.

A 16-Week Randomized, Open Labelled, Four-Armed, Treat-to-Target, Parallel-Group Trial Comparing Three Different Dosing Levels of An Investigational Insulin and Insulin Glargine Once Daily, All in Combination with Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment

A 16-Week Randomized, Open Labeled, Three-Armed, Treat-to-Target, Parallel Group Trial Comparing Two Different Doses of An Investigational Insulin+NovoRapid and Insulin Glargine Once Daily+NovoRapid, All in a Basal/Bolus Regimen in Subjects with Type I Diabetes.

Collection of normal blood sample for use in genetic studies for Colon Cancer

Randomized, Double Blind, Parallel Group, Placebo Controlled Multicenter Study Evaluating the Efficacy of An Investigational Medication BID and Celecoxib 300 mg QD in Patients with Osteoarthritis of the Knee

A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Efficacy and Safety Trial to Evaluate the Effect of an Investigational Medication on Weight in Obese and Overweight Subjects

The Effect of Dose Titration of an Investigational Medication in Overweight and Obese Patients with Type 2 Diabetes Mellitus

A Multicenter, Blinded, Randomized, Placebo-Controlled Study of A Topical Gel in Patients With Painful Diabetic Neuropathy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 9-Week, Dose Ranging Study of An Investigational Medication in the Treatment of Mild to Moderate Hypertension

A Study of An Investigational Medication Versus Enalapril in Patients With Mild to Moderate Hypertension

A Randomized, Double-Blind Safety and Efficacy Study of Two Marketed Antihypertensive Medications as First-Line Therapy After 6 Weeks In Patients with Severe Hypertension

A Phase II, Randomized, Double Blind, Placebo and Active Controlled, Parallel Group, Multicenter, Dose Ranging Study to Evaluate the Efficacy and Safety of An Investigational Medication Compared to Placebo After 8 Weeks Treatment if Patients with Resistant Hypertension

A Worldwide, Multicenter, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of An Investigational Medication When Added to Ongoing Therapy With Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) in Patients With Diabetes and Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Forced-Titration Study of the Safety and Effectiveness of An Investigational Medication vs. Placebo in Japanese-American and Caucasian-American Patients With Hypercholesterolemia

An Open-Label, Randomized Study of the Relative Efficacy of an Investigational Medication Compared to Simvastatin and Atorvastatin

A Double-Blind Comparison of Two New Dose Levels of An Investigational Medication with Placebo in Hypercholesterolemic Subjects

A Randomized, Double Blind, Placebo-Controlled, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Treatment With An Investigational Medication in Thiazolidinedione-Treated (Pioglitazone or Rosiglitazone) Type 2 Diabetic Patients

A Multicenter, Randomized, Placebo-Controlled, “factorial”design, 12-Month Study to Evaluate the Efficacy and Safety of an Investigational Medication 25mg/Day and 50mg/Day co-administered with all registered Atorvatatin Stengths Ranging from 10mg to 80mg in Patients with Primary Hypercholesterolemia